Evidence map›Paper›PMID 31131537›Full record

ArticleMolecular oncology2019

Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.

Wenbo Yuan, Rui Zhou, Jingzi Wang, Jie Han, Xiao Yang, Hao Yu, Hongcheng Lu, Xiaolei Zhang, Pengchao Li, Jun Tao and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Circular RNA in cancer.Nature reviews. Cancer · 2024
    Review
  17. Article
  18. Review
  19. NCellular & molecular biology letters · 2024
    Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Wenbo YuanDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Rui ZhouDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Jingzi WangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Jie HanDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Xiao YangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Hao YuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Hongcheng LuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Xiaolei ZhangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Pengchao LiDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Jun TaoDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Jifu WeiResearch Division of Clinical Pharmacology, The First Affiliated Hospital of Nanjing Medical University, China.
Qiang LuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Haiwei YangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Min GuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, China.
Jiangsu Province Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNAs (circRNAs) have recently emerged as essential regulators in carcinogenesis and cancer progression. Previous studies have shown that Cdr1as functions as a microRNA (miRNA) sponge in various cancer types. However, the role of Cdr1as in cisplatin chemosensitivity in bladder cancer remains unclear. Here, we used real-time PCR to examine miRNA and gene expression in bladder cancer tissues and cell lines. The abilities of Cdr1as and its downstream regulatory molecules to induce apoptosis and promote cisplatin-induced chemosensitivity of bladder cancer cells were determined by flow cytometry and cell counting kit. Bioinformatic analysis was utilized to predict potential miRNA target sites, and biotin-coupled miRNA capture, biotin-coupled probe pull-down assay, and RNA fluorescent in situ hybridization were used to study the interaction between Cdr1as and target miRNAs. Dual-luciferase reporter assay was also used to validate the target genes of miRNAs. The expression level of apoptotic protease-activating factor 1 (APAF1) in bladder cancer cells was identified via western blot. Finally, the sensitivity of Cdr1as to cisplatin chemotherapy in nude mice xenografts was evaluated in terms of the size, volume of tumors, and the survival of mice. We report that Cdr1as induced the apoptosis and enhanced the cisplatin chemosensitivity of bladder cancer cells both in vitro and in vivo. Silencing of APAF1 reduced the sensitivity of bladder cancer cells to cisplatin chemotherapy. Furthermore, Cdr1as could directly sponge miR-1270 and abolish its effect on APAF1. Our study verified that Cdr1as exerts a cisplatin-chemosensitization effect on bladder cancer cells through the Cdr1as/miR-1270/APAF1 axis. This newly identified axis may be a potential therapeutic target for bladder cancer patients.

Indexed as

AnimalsAntineoplastic AgentsApoptosisApoptotic Protease-Activating Factor 1Cell Line, TumorCisplatinFemaleGene Expression Regulation, NeoplasticHumansMice, Inbred BALB CMice, NudeMicroRNAsRNA, CircularUp-RegulationUrinary Bladder NeoplasmsAntineoplastic AgentsAPAF1 protein, humanApoptotic Protease-Activating Factor 1CisplatinMicroRNAsMIRN1270 microRNA, humanRNA, CircularAPAF1bladder cancerCdr1ascircular RNAcisplatinmiR-1270

Identifiers

PMID31131537
PMCPMC6599840
OpenAlexW2947557052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.